Molecular structure of Vitamin D2, 1a-Hydroxy-, CAS Number: 54573-75-0
Vitamin D2, 1a-Hydroxy- (CAS 54573-75-0)
Alternate Names:
Doxercalciferol
Application:
Vitamin D2, 1a-Hydroxy- is an analog of vitamin D2 and is a VDR activator
CAS Number:
54573-75-0
Purity:
≥98%
Molecular Weight:
412.7
Molecular Formula:
C28H44O2
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Vitamin D2, 1a-Hydroxy- is a vitamin D2 analog. The compound is metabolized to the natural active dihydroxylated metabolite of vitamin D2, 1α,25-dihydroxyvitamin D2.
Vitamin D2, 1a-Hydroxy- (CAS 54573-75-0) References
- Pharmacokinetics of doxercalciferol, a new vitamin D analogue that lowers parathyroid hormone. | Upton, RA., et al. 2003. Nephrol Dial Transplant. 18: 750-8. PMID: 12637645
- Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. | Coburn, JW., et al. 2004. Am J Kidney Dis. 43: 877-90. PMID: 15112179
- Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol. | Zisman, AL., et al. 2005. Am J Nephrol. 25: 591-5. PMID: 16282676
- Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome. | Petrich, A., et al. 2008. Leuk Lymphoma. 49: 57-61. PMID: 18203012
- Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist. | Zhang, Y., et al. 2009. Am J Physiol Renal Physiol. 297: F791-801. PMID: 19535571
- A new look at the most successful prodrugs for active vitamin D (D hormone): alfacalcidol and doxercalciferol. | Kubodera, N. 2009. Molecules. 14: 3869-80. PMID: 19924035
- A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease. | Moe, SM., et al. 2010. Clin J Am Soc Nephrol. 5: 299-306. PMID: 20056760
- Comparison of the pharmacological effects of paricalcitol and doxercalciferol on the factors involved in mineral homeostasis. | Wu-Wong, JR., et al. 2010. Int J Endocrinol. 2010: 621687. PMID: 20204178
- Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. | Wesseling-Perry, K., et al. 2011. Kidney Int. 79: 112-9. PMID: 20861820
- Comparative effects of doxercalciferol (1α-hydroxyvitamin D₂) versus calcitriol (1α,25-dihydroxyvitamin D₃) on the expression of transporters and enzymes in the rat in vivo. | Chow, EC., et al. 2011. J Pharm Sci. 100: 1594-604. PMID: 20967888
- Direct suppression of Pth gene expression by the vitamin D prohormones doxercalciferol and calcidiol requires the vitamin D receptor. | Ritter, CS. and Brown, AJ. 2011. J Mol Endocrinol. 46: 63-6. PMID: 21169421
- Vitamin D receptor agonist doxercalciferol modulates dietary fat-induced renal disease and renal lipid metabolism. | Wang, XX., et al. 2011. Am J Physiol Renal Physiol. 300: F801-10. PMID: 21209008
- Doxercalciferol, a pro-hormone of vitamin D, prevents the development of cardiac hypertrophy in rats. | Choi, JH., et al. 2011. J Card Fail. 17: 1051-8. PMID: 22123370
- Metabolism of 1 alpha-hydroxyvitamin D2 to activated dihydroxyvitamin D 2 metabolites decreases endogenous 1 alpha, 25-dihydroxyvitamin D 3 in rats and monkeys. | Knutson, JC., et al. 1995. Endocrinology. 136: 4749-53. PMID: 7588202
- 1 alpha-Hydroxy-vitamin D2: a new look at an 'old' compound. | Coburn, JW., et al. 1996. Nephrol Dial Transplant. 11 Suppl 3: 153-7. PMID: 8840332
Inhibitor of:
CYP24, and PHEX.Activator of:
VDR.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Vitamin D2, 1a-Hydroxy-, 1 mg | sc-205886 | 1 mg | $60.00 |